Feb 17, 2021
Blueprint Medicines Reports Fourth Quarter and Full Year 2020 Financial Results
Feb 10, 2021
Blueprint Medicines to Report Fourth Quarter and Full Year 2020 Financial Results on Wednesday, February 17, 2021
Feb 05, 2021
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Jan 11, 2021
Blueprint Medicines Announces R&D Leadership Transitions
Jan 11, 2021
Blueprint Medicines Reports Portfolio Milestones and Outlines 2021 Roadmap for Precision Medicine Leadership
Jan 05, 2021
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Dec 17, 2020
Blueprint Medicines Submits Supplemental New Drug Application to FDA for AYVAKIT(TM) (avapritinib) for the Treatment of Advanced Systemic Mastocytosis
Dec 07, 2020
Blueprint Medicines Data Presented at 62nd ASH Annual Meeting and Exposition Highlight Broad Commitment to Advance Patient Care in Systemic Mastocytosis
Dec 01, 2020
Blueprint Medicines Announces FDA Approval of GAVRETO(TM) (pralsetinib) for the Treatment of Patients with Advanced or Metastatic RET-Mutant and RET Fusion-Positive Thyroid Cancer
Nov 23, 2020
Blueprint Medicines To Present Broad Range of Data Reinforcing Commitment to Advance Patient Care in Systemic Mastocytosis at 62nd ASH Annual Meeting and Exposition
Oct 29, 2020
Blueprint Medicines Reports Third Quarter 2020 Financial Results
Oct 22, 2020
Blueprint Medicines to Report Third Quarter 2020 Financial Results on Thursday, October 29, 2020
Sep 17, 2020
Blueprint Medicines Presents Foundational Preclinical Data for BLU-945 Showing Robust Anti-Tumor Activity in Treatment-Resistant EGFR-Mutated Lung Cancer at ESMO Virtual Congress 2020
Sep 09, 2020
Blueprint Medicines to Present at 18th Annual Morgan Stanley Global Healthcare Conference
Sep 01, 2020
Blueprint Medicines Strengthens Leadership with Appointment of Fouad Namouni, M.D., as President, Research & Development
Aug 04, 2020
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Jul 30, 2020
Blueprint Medicines Reports Second Quarter 2020 Financial Results
Jul 23, 2020
Blueprint Medicines to Report Second Quarter 2020 Financial Results on Thursday, July 30, 2020
Jul 14, 2020
Blueprint Medicines Announces Global Collaboration with Roche to Develop and Commercialize Pralsetinib for Patients with RET-Altered Cancers
Jul 02, 2020
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)